279 related articles for article (PubMed ID: 29576445)
1. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.
Koshkin VS; Barata PC; Rybicki LA; Zahoor H; Almassi N; Redden AM; Fergany AF; Kaouk J; Haber GP; Stephenson AJ; Ornstein MC; Gilligan T; Garcia JA; Rini BI; Grivas P
Clin Genitourin Cancer; 2018 Aug; 16(4):e879-e892. PubMed ID: 29576445
[TBL] [Abstract][Full Text] [Related]
2. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients.
Thompson RH; Boorjian SA; Kim SP; Cheville JC; Thapa P; Tarrel R; Dronca R; Costello B; Frank I
BJU Int; 2014 May; 113(5b):E17-21. PubMed ID: 24006893
[TBL] [Abstract][Full Text] [Related]
3. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
Dash A; Galsky MD; Vickers AJ; Serio AM; Koppie TM; Dalbagni G; Bochner BH
Cancer; 2006 Aug; 107(3):506-13. PubMed ID: 16773629
[TBL] [Abstract][Full Text] [Related]
4. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
5. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
[No Abstract] [Full Text] [Related]
6. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
8. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
[TBL] [Abstract][Full Text] [Related]
9. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Krabbe LM; Westerman ME; Margulis V; Raj GV; Sagalowsky AI; Courtney K; Arriaga Y; Lotan Y
Can J Urol; 2015 Aug; 22(4):7865-75. PubMed ID: 26267024
[TBL] [Abstract][Full Text] [Related]
10. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
11. Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study.
Hinata N; Hussein AA; George S; Trump DL; Levine EG; Omar K; Dasgupta P; Khan MS; Hosseini A; Wiklund P; Guru KA
BJU Int; 2017 Apr; 119(4):605-611. PubMed ID: 27743481
[TBL] [Abstract][Full Text] [Related]
12. Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival.
Patel HD; Patel SH; Blanco-Martinez E; Kuzbel J; Chen VS; Druck A; Koehne EL; Patel PM; Doshi CP; Hahn NM; Hoffman-Censits JH; Berg S; Bivalacqua TJ; Kates M; Quek ML
J Urol; 2022 Jan; 207(1):77-85. PubMed ID: 34445890
[TBL] [Abstract][Full Text] [Related]
13. Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Pak JS; Haas CR; Anderson CB; DeCastro GJ; Benson MC; McKiernan JM
Urol Oncol; 2021 Nov; 39(11):787.e9-787.e15. PubMed ID: 33865688
[TBL] [Abstract][Full Text] [Related]
14. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.
Peyton CC; Tang D; Reich RR; Azizi M; Chipollini J; Pow-Sang JM; Manley B; Spiess PE; Poch MA; Sexton WJ; Fishman M; Zhang J; Gilbert SM
JAMA Oncol; 2018 Nov; 4(11):1535-1542. PubMed ID: 30178038
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
[TBL] [Abstract][Full Text] [Related]
16. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.
Rose TL; Deal AM; Basch E; Godley PA; Rathmell WK; Kim WY; Whang YE; Dunn MW; Wang A; Chen RC; Nielsen ME; Pruthi RS; Wallen EM; Woods ME; Smith AB; Milowsky MI
Urol Oncol; 2015 Sep; 33(9):386.e1-6. PubMed ID: 26122712
[TBL] [Abstract][Full Text] [Related]
18. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
[TBL] [Abstract][Full Text] [Related]
20. Administration of neoadjuvant chemotherapy for muscle-invasive bladder cancer in real life: Are urologists still too cautious?
Such M; Lavolle A; Popelin MB; Thibault C; Fontaine E; Dariane C; Oudard S; Mejean A; Timsit MO; Audenet F
Prog Urol; 2021 May; 31(6):332-339. PubMed ID: 33468415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
